Dr. Oxnard Discusses the Circulating Cell-Free Genome Atlas Study

Geoffrey R. Oxnard, MD
Published: Sunday, Jun 03, 2018



Geoffrey R. Oxnard, MD, associate professor of medicine, Harvard Medical School, thoracic oncologist, medical oncology, Dana-Farber Cancer Institute, discusses the design and importance of the Circulating Cancer Genome Atlas (CCGA) study in an interview with OncLive during the 2018 ASCO Annual Meeting.

Initial data from the CCGA study suggest that cell-free DNA assays can be used with a high degree of specificity to detect signs of early stage lung cancer.

Moreover, the study included 3 types of prototype sequencing assays. These included paired cfDNA and white blood cell targeted sequencing for single nucleotide variants/indels, paired cfDNA and WBC whole genome sequencing for copy number variation, and cfDNA whole genome bisulfite sequencing for methylation.

<<< 2018 ASCO Annual Meeting


Geoffrey R. Oxnard, MD, associate professor of medicine, Harvard Medical School, thoracic oncologist, medical oncology, Dana-Farber Cancer Institute, discusses the design and importance of the Circulating Cancer Genome Atlas (CCGA) study in an interview with OncLive during the 2018 ASCO Annual Meeting.

Initial data from the CCGA study suggest that cell-free DNA assays can be used with a high degree of specificity to detect signs of early stage lung cancer.

Moreover, the study included 3 types of prototype sequencing assays. These included paired cfDNA and white blood cell targeted sequencing for single nucleotide variants/indels, paired cfDNA and WBC whole genome sequencing for copy number variation, and cfDNA whole genome bisulfite sequencing for methylation.

<<< 2018 ASCO Annual Meeting



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Working Group to Optimize Outcomes in EGFR-mutated Lung Cancers: Evolving Concepts for Nurses to Facilitate and Improve Patient CareJun 30, 20181.5
Community Practice Connections™: 4th Annual Miami Lung Cancer Conference®Jun 30, 20187.0
Publication Bottom Border
Border Publication
x